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Abstract
Introduction Obesity is a risk factor for postmenopausal breast
cancer and is associated with shortened mammary tumor (MT)
latency in MMTV-TGF-α mice with dietary-induced obesity. One
link between obesity and breast cancer is the adipokine, leptin.
Here, the focus is on diet-induced obesity and MT and mammary
fat pad (MFP) leptin and apoptotic signaling proteins.
Methods MMTV-TGF-α mice were fed low-fat or high-fat diets
from 10 to 85 weeks of age. High-Fat mice were divided into
Obesity-Prone and Obesity-Resistant groups based on final
body weights. Mice were followed to assess MT development
and obtain serum, MFP, and MT.
Results Incidence of palpable MTs was significantly different:
Obesity-Prone > Obesity-Resistant > Low-Fat. Serum leptin
was significantly higher in Obesity-Prone compared with
Obesity-Resistant and Low-Fat mice. Low-Fat mice had higher
MFP and MT ObRb (leptin receptor) protein and Jak2 (Janus
kinase 2) protein and mRNA levels in comparison with High-Fat
mice regardless of body weight. Leptin (mRNA) and pSTAT3
(phosphorylated signal transducer and activator of transcription
3) (mRNA and protein) also were higher in MTs from Low-Fat
versus High-Fat mice. Expression of MT and MFP pro-apoptotic
proteins was higher in Low-Fat versus High-Fat mice.
Conclusion These results confirm a connection between body
weight and MT development and between body weight and
serum leptin levels. However, diet impacts MT and MFP leptin
and apoptosis signaling proteins independently of body weight.
Introduction
Breast cancer is the most common malignancy for women
worldwide, with more than one million women diagnosed each
year [1-3]. Although genetic mutations increase the risk for
development of breast cancer, this impacts only a small per-
centage of women. Reproductive and lifestyle factors increas-
ingly are implicated to play a role in breast cancer
development [4]. Obesity is one of the lifestyle factors thought
to affect the risk for postmenopausal breast cancer [5] and is
associated with increased mortality in women diagnosed with
breast cancer [6,7]. Obesity, in turn, impacts levels of serum
estrogen, insulin, and/or insulin-like growth factor-1, which
have all been implicated as possible links between obesity and
breast cancer [8-12]. Leptin, a protein secreted primarily from
adipose tissue [13-16], also has been implicated as a mam-
mary tumor (MT) growth factor. For example, increased cell
proliferation was observed when human breast cancer cells
were incubated with leptin in in vitro studies [17-19]. Addition-
ally, the leptin receptor was identified in breast cancer cell
lines and in human breast cancer tissues [17-19].
Animal models are frequently used to gain insights into human
disease processes. In general, higher body weights and/or
obesity has been associated with shortened MT latency and/
or increased incidence for development of spontaneous and
carcinogen-induced MT in animals [20-25]. An exception
ANOVA = analysis of variance; bp = base pairs; ECF = enhanced chemifluorescence; IgG = immunoglobulin G; Jak2 = Janus kinase 2; MFP = mam-
mary fat pad; MT = mammary tumor; pAkt = phosphorylated Akt; PARP = poly(ADP-ribose)polymerase; pSTAT3 = phosphorylated signal transducer 
and activator of transcription 3; PVDF = polyvinylidene difluoride; RT-PCR = reverse transcription-polymerase chain reaction; SEM = standard error 
of the mean; STAT3 = signal transducer and activator of transcription 3.Breast Cancer Research    Vol 9 No 6    Dogan et al.
Page 2 of 15
(page number not for citation purposes)
noted was that genetically obese LepobLepob  mice were
reported to have a decreased incidence of spontaneous MTs
[26], and recently our laboratory found that when Lep strain
mice were crossbred with transgenic MMTV-TGF-α mice,
obese MMTV-TGF-α-LepobLepob mice did not develop onco-
gene-induced MTs, although their lean littermates did [27].
The metabolic defect in LepobLepob mice is an absence of lep-
tin [28]. In a second study, Lepr mice that exhibit a mutation in
the leptin receptor were crossbred with MMTV-TGF-α mice
and again no MTs were detected in obese MMTV-TGF-α-Lep-
rdbLeprdb mice [29]. One could argue that MMTV-TGF-α MTs
are not affected by obesity; but in an additional experiment,
MMTV-TGF-α mice with diet-induced obesity had shortened
MT latency [30]. Thus, in the presence of a functioning leptin
axis, MTs develop. These findings led us to hypothesize that
leptin is a growth factor for breast/mammary cancer cells.
In the present study, we used a dietary-induced obesity proto-
col to further explore the relationship of serum leptin levels and
body weight with respect to MT development in MMTV-TGF-
α mice. Leptin signaling proteins in MT and mammary fat pad
(MFP) tissues were characterized. Although six different leptin
receptor subtypes have been identified in numerous tissues
and cell types, primarily the long isoform (ObRb) is responsi-
ble for activating leptin signaling pathways [31,32]. In this
study, we determined expression of the total leptin receptor
(ObR) as well as ObRb. Leptin acts through several signaling
pathways, including Jak2/STAT3 (Janus kinase 2/signal trans-
ducer and activator of transcription 3) and PI3K/Akt [33-36],
and here we determined protein and/or mRNA expression lev-
els for these pathways. Another metabolic action of leptin that
has been reported is inhibition of apoptosis in human colon
[37] and prostate [38] cancer cell lines and in leukemic cells
[39]. Thus, proteins involved in apoptosis (that is, total poly
[ADP-ribose]polymerase [PARP], PARP [89 kDa], PARP [24
kDa], Bax, Bcl-2, and Bcl-xL) as well as caspase-3 activity
were determined in MT and MFP tissues in the present study.
Materials and methods
Materials
Primary antibodies against Ob, ObR, phosphorylated STAT3
(pSTAT3), Jak2, phosphorylated Akt (pAkt), Bcl-2, Bcl-xL, Bax,
and alkaline phosphatase-conjugated goat anti-mouse immu-
noglobulin G (IgG) were purchased from Santa Cruz Biotech-
nology, Inc. (Santa Cruz, CA, USA). ObRb was purchased
from Linco Research, Inc. (now part of Millipore Corporation,
Billerica, MA, USA). PARP (#9542) and anti-rabbit IgG conju-
gated with alkaline phosphatase were purchased from Cell
Signaling Technology, Inc. (Danvers, MA, USA). β-Actin was
purchased from Delta Biolabs, LLC (Gilroy, CA, USA).
Enhanced chemifluorescence (ECF) substrate was obtained
from Amersham Biosciences (now part of GE Healthcare, Lit-
tle Chalfont, Buckinghamshire, UK). Tris-base solution, Tris/
Glycine/SDS buffer, and polyacrylamide gradient gels were
purchased from Bio-Rad Laboratories, Inc. (Hercules, CA,
USA). Reverse transcriptase (Superscript II) and oligo(dT)
were purchased from GibcoBRL (now part of Invitrogen Cor-
poration, Carlsbad, CA, USA). Polyvinylidene difluoride
(PVDF) membranes (Immobilon-P) were from Millipore Corpo-
ration. Immunoglobulin-alcaline phosphatase-conjugated sec-
ondary antibodies were purchased from Amersham Life
Science Inc. (now part of GE Healthcare).
Animals and study design
MMTV-TGF-α (C57BL6) female mice were produced and
genotyped at the Hormel Institute (Austin, MN, USA) as previ-
ously described [40]. Mice were randomly assigned at 10
weeks of age to either a Low-Fat group fed commercial rodent
diet (3.3 kcal/g) (n = 20) or to a High-Fat group fed a moder-
ately high-fat diet consisting of 48% rodent diet, 44% con-
densed milk, and 8% corn oil (4.47 kcal/g) (n = 50). Mice were
individually caged, and food intakes and body weights were
determined weekly, at which time mice were palpated to iden-
tify the presence of MTs. Once MTs were detected, growth
was monitored with calipers. Mice fed the high-fat diet with
final body weights ± 2 standard deviations of Low-Fat mice
were classified as Obesity-Resistant (n = 17). The remaining
High-Fat mice were designated as Obesity-Prone (n = 33).
Mice were euthanized when MT size reached 20 mm or at 85
weeks of age. When possible, blood samples were obtained
by cardiac puncture before the mice were euthanized and
serum prepared for leptin measurement. Serum leptin levels
were determined using a commercial kit in accordance with
the manufacturer's protocol (Linco Mouse Leptin Kit; Millipore
Corporation). MTs and parametrial and retroperitoneal fat
pads were removed and weighed. MFP samples were
obtained but not weighed. MTs and tissue samples that
appeared abnormal were preserved in formalin and sent to the
Department of Pathology and Laboratory Medicine of the
Mayo Foundation (Rochester, MN, USA) for histopathological
analyses to determine malignancy and/or disease status. The
remaining tissue was stored at -80°C until used. All proce-
dures with mice were performed under the guidelines and with
approval of the University of Minnesota Institutional Animal
Care and Use Committee.
Western blot analysis of mammary tumor and mammary 
fat pad proteins
Tissue samples were homogenized in extraction buffer with
protease inhibitors. Total protein was extracted using a Total
Protein Extraction Kit (Chemicon International, Temecula, CA,
USA) and quantitated using a Bio-Rad protein assay kit with
bovine serum albumin as a standard (Bio-Rad Laboratories,
Inc.). Extracted proteins were electrophoresed on 4% to 15%
polyacrylamide gradient gels and then transferred to a PVDF
membrane. Blots were blocked in Tris-Base solution contain-
ing 1% milk concentrate and 0.15% Tween-20. The PVDF
membranes were incubated with appropriate primary antibod-
ies against leptin signaling proteins (leptin, long [ObRb] and
total [ObR] forms of the leptin receptors, Jak2, pAkt, andAvailable online http://breast-cancer-research.com/content/9/6/R91
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pSTAT3) and apoptosis signaling proteins (Bcl-2, Bcl-xL, Bax,
and PARP) in MFP and MT samples. YES Membranes were
next incubated with a secondary antibody conjugated to alka-
line phosphatase. ECF substrate was used to visualize the
bands using a Storm 840 Machine Imaging System (Molecular
Dynamics, Sunnyvale, CA, USA). Standard molecular weight
markers were run simultaneously for comparing molecular
weights of the visualized proteins. The intensity of Western
blot bands was quantified by densitometric analysis using the
program UN-SCAN-IT gel (Silk Scientific, Inc., Orem, UT,
USA). Results were expressed as the ratio of intensity of the
protein of interest to that of β-actin from the same sample.
Although some mice had more than one MT, only one MT per
animal was analyzed. For each measurement, 'n' is 3 to 6 for
MT and 4 to 6 for MFP samples, as indicated in figure legends.
Because no differences were found for MT and MFP samples
from Obesity-Prone and Obesity-Resistant mice, these results
were combined and designated as High-Fat.
Measurement of caspase-3 activity in mammary tumor 
and mammary fat pad
Caspase-3 activity was determined as described in the manu-
facturer's protocol (R&D Systems, Inc., Minneapolis, MN,
USA), using the same protein sample prepared for Western
blot analysis. This assay is based on detection of cleavage of
the substrate DEVD-AFC. The assay was carried out in 96-
well flat-bottom microplates. Briefly, 100 μg of protein for MT
and 150 μg of protein for MFP samples were incubated with
200 μM Ac-DEVD-pNA caspase-3 substrate in 50 μL of cas-
pase assay buffer at 37°C for 4 hours. The release of pNA was
measured at 400-nm excitation and 505-nm emission using a
fluorometric Fluoroskan Ascent plate reader (Labsystem, now
part of Thermo Fisher Scientific, Inc. Waltham, MA, USA). The
fluorescence value obtained with the substrate, but without
sample protein, was used as a background/negative control.
Caspase-3 activity levels were calculated by subtracting the
background value from the sample value. Each sample was
run in duplicate. Values from the Low-Fat group were taken as
100%, and results from the High-Fat group were calculated
relative to the Low-Fat group as a percentage.
RT-PCR analysis of mRNA expression in mammary 
tumor and mammary fat pad samples
mRNA expression levels of leptin and long form (ObRb) and
total form (ObR) of leptin receptors and STAT3 were meas-
ured in MT and MFP samples using reverse transcription-
polymerase chain reaction (RT-PCR) analysis. Briefly, total
RNA was extracted from equal amounts of frozen tissue sam-
ples using an RNeasy mini kit in accordance with the manufac-
turer's protocol (Qiagen Inc., Valencia, CA, USA). Isolated
total RNA was quantified using a spectrophotometer, and
equal amounts of RNA from each tissue were used for RT-
PCR. Total RNA was reverse-transcribed using random hex-
amers, RNase inhibitor, reverse transcriptase (Superscript II),
and oligo(dT) primers to synthesize first-strand cDNA from
mRNA (Invitrogen Corporation). Total volume was adjusted to
50 μL using DNase- and RNase-free water. PCR primers were
designed using nucleotide sequence for mouse ObR (Gen-
Bank accession number: U42467), ObRb (GenBank acces-
sion number: U58861), leptin (GenBank accession number:
NM_008493), and STAT3 (GenBank accession number:
U06922). The following primers were used: ObR, forward 5'-
CAGATTCGATATGGCTTAAGT-3' and reverse 5'-
GTTAAAATTCACAAGGGAAGC-3'; ObRb, forward 5'-
ACACTGTTAATTTCACACCAGAG-3' and reverse 5'-TGGA-
TAAACCCTTGCTCTTCA-3'; leptin, forward 5'-CCTGT-
GGCTTTGGTCCTATCTG-3' and reverse 5'-
AGGCAGGCTGGTGAGGACCTG-3'; and STAT3, forward
5'-CAGGGTGTCAGATCACATGG-3' and reverse 5'-TTATT-
TCCAAACTGCATCAATG-3'.
These primers gave final product sizes of 475, 446, 244, and
600 base pairs (bp) for ObR, ObRb, leptin, and STAT3,
respectively. PCR was performed under the following condi-
tions: 94°C for 4 minutes for denaturing, 35 cycles of 94°C for
30 seconds, 62°C for 30 seconds, 72°C for 1 minute, and
final extension at 72°C for 10 minutes. Reactions were carried
out in a final volume of 25 μL in a thermocycler in the presence
of Taq DNA polymerase. Water was used as the negative con-
trol, and mouse β-actin primers that produce a product of
approximately 600 bp were used as internal controls. PCR
products were separated on 1% agarose gel and stained with
ethidium bromide, and product size was determined by con-
currently separating 100-bp DNA ladder on the same gel. The
DNA gel was scanned, the intensity of bands was quantified
by densitometry using the program UN-SCAN-IT gel (Silk Sci-
entific, Inc.), and results were expressed as the ratio of inten-
sity of the gene of interest to that of β-actin in samples from
individual mice. DNA obtained from tissue samples was run on
agarose gel and subsequently extracted. The samples were
sent to the Advanced Genetic Analysis Center of the Univer-
sity of Minnesota (St. Paul, MN, USA) for sequencing to con-
firm that the bands analyzed are the genes of interest (that is,
ObR, ObRb, leptin, and STAT3).
Statistical analysis
Results are presented as mean ± standard error of the mean
(SEM). Tumor incidence data were analyzed by the chi-square
test and Fisher exact test, and latency data were analyzed by
the proportional hazard model using the Low-Fat group as the
reference. Comparisons among three groups were made by
analysis of variance (ANOVA) followed by the Newman-Keuls
test to determine differences between specific groups. When
only High-Fat versus Low-Fat groups were compared, the Stu-
dent t test was used. The Pearson correlation test was used to
determine whether the correlation between two parameters
was significant.Breast Cancer Research    Vol 9 No 6    Dogan et al.
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Results
Caloric intake, body and fat pad weights, and serum 
leptin
There were no differences in caloric intake among the groups:
Obesity-Prone, 9,481 ± 193 (n  = 18); Obesity-Resistant,
8,647 ± 216 (n = 11); and Low-Fat, 9,157 ± 387 (n = 19)
(values are mean ± SEM, ANOVA p = 0.219, calculated for
mice that lived to the termination of the study). Obesity-Prone
mice were 45% heavier than either Obesity-Resistant or Low-
Fat mice at the termination of the experiment (p  < 0.001)
(Table 1). Additionally, combined retroperitoneal and parame-
trial fat pad weights of Obesity-Prone mice were 4.5 and 9
times heavier than those of Obesity-Resistant and Low-Fat
mice, respectively (Table 1). Interestingly, fat pads from Obes-
ity-Resistant mice were twice as heavy as those of Low-Fat
mice despite the similar body weights of these two groups.
However, the fat pad weights for Obesity-Resistant and Low-
Fat mice were not significantly different by the Newman-Keuls
test following ANOVA, when these values were analyzed by
Student t test (p = 0.0174). Serum leptin levels were signifi-
cantly higher in Obesity-Prone mice compared with Obesity-
Resistant (p < 0.01) and Low-Fat (p < 0.001) mice (Table 1).
Similar to fat pad weights, Obesity-Resistant mice had serum
leptin levels that were twice those of Low-Fat diet mice; again,
this difference was not significant using the Newman-Keuls
test following ANOVA but was significantly different when
compared by the Student t test (p < 0.03). When data from all
mice were pooled, there was a significantly (p < 0.0001) pos-
itive correlation of fat pad and body weights to serum leptin
levels (Figure 1a,b). Similar results were obtained for individual
groups (data not shown).
Mammary tumor development
Obesity-Prone mice had an overall MT incidence of 79% com-
pared with 71% for Obesity-Resistant mice and 55% for Low-
Fat mice (Table 2). Overall MT incidence is defined as (a) all
MTs classified as adenocarcinomas and initially detected by
palpation and (b) those nonpalpable MTs discovered at
necropsy. These values were not significantly different from
each other, although chi-square analysis between Obesity-
Prone and Low-Fat mice had a p value of 0.07. When inci-
dence rates for palpable MTs were determined, values were
55%, 29%, and 10% for Obesity-Prone, Obesity-Resistant,
and Low-Fat mice, respectively. These results were signifi-
cantly different for comparisons among the groups (p  =
0.0038) with specific differences between Obesity-Prone and
Obesity-Resistant (p = 0.09), Obesity-Prone and Low-Fat (p =
0.0012), and Obesity-Resistant and Low-Fat (p = 0.21) (Table
2).
There was a significant difference among the groups with
respect to age of palpable MT detection (Table 2). There was
also a significant difference between the Low-Fat and Obesity-
Prone groups of almost 8 weeks. The latency for overall MT
development is not shown as the results are affected by the
fact that most of the MTs in the Low-Fat and Obesity-Resistant
groups were found at 85 weeks of age, when the mice were
euthanized because this was the termination point of the
study.
Average MT weights per tumor-bearing mouse were 2.41,
1.30, and 0.65 g for Obesity-Prone, Obesity-Resistant, and
Low-Fat mice (p = 0.0016), respectively (Table 2). Although
the average MT weight for Obesity-Resistant mice was twice
that of Low-Fat mice, this did not reach statistical significance.
There was a trend toward increased MT number per tumor-
bearing mouse for mice fed the high-fat diet regardless of
body weight classification; however, this did not reach statisti-
cal significance either. Interestingly, six Obesity-Prone mice
had MTs classified as high-grade adenocarcinoma compared
with none for the other two groups.
Leptin signaling protein and mRNA expression in 
mammary tumor and mammary fat pad
Because there were no significant differences between Obes-
ity-Prone and Obesity-Resistant mice, protein expression lev-
els for these two groups were combined and termed High-Fat.
Protein expression levels of ObRb, Jak2, and pSTAT3 were
significantly lower in MT samples from High-Fat mice com-
pared with those from Low-Fat mice (p < 0.05) (Figure 2a). On
the other hand, leptin and ObR protein expression levels were
similar between the two groups. In addition, MTs obtained
from Low-Fat mice had significantly higher mRNA expression
levels of leptin, ObR, ObRb, and STAT3 (p < 0.01) than those
of High-Fat mice (Figure 2b).
Table 1
Body and fat pad weights and serum leptin for Obesity-Prone, Obesity-Resistant, and Low-Fat MMTV TGF-α mice
Body weight (g) Fat pad weight (g) Serum leptin (ng/mL)
Obesity-Prone 40.49 ± 1.03a,b (n = 33) 3.512 ± 0.41b (n = 33) 10.56 ± 1.95b (n = 25)
Obesity-Resistant 28.57 ± 0.51c (n = 17) 0.786 ± 0.15c (n = 17) 3.61 ± 1.11c (n = 10)
Low-Fat 27.28 ± 0.56c (n = 20) 0.389 ± 0.05c (n = 20) 1.58 ± 0.15c (n = 16)
Overall significance P < 0.001 P < 0.001 P < 0.001
aValues are mean ± standard error of the mean. Different superscripts (b and c) indicate significant difference by Newman-Keuls test following 
analysis of variance.Available online http://breast-cancer-research.com/content/9/6/R91
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MFP samples from High-Fat mice exhibited significantly lower
protein levels of ObRb and Jak2 compared with MFP from
Low-Fat mice (p < 0.05) (Figure 3a). However, there were no
significant differences between MFP samples from Low-Fat
and High-Fat mice for leptin, ObR, and pSTAT3 protein levels.
Expressions of ObR and ObRb mRNA levels were significantly
higher in MFP of Low-Fat compared with High-Fat mice (Fig-
ure 3b). However, leptin and STAT3 mRNA expression levels
were similar in MFP samples from both groups (Figure 3b).
Apoptosis signaling proteins in mammary tumor and 
mammary fat pad
To investigate the effects of body weight and diet on the apop-
tosis signaling pathway, a number of protein expression levels
were determined. Total PARP (116 kDa) and two of its
cleaved products (89 and 24 kDa) in MT and MFP tissues
were measured. Low-Fat mice had significantly higher (3.5-
fold) levels of total and cleaved PARP products in MTs com-
pared with High-Fat mice (p < 0.01) (Figure 4a–c). In MFP of
Figure 1
Correlation of serum leptin levels with fat pad and body weight in MMTV-TGF-α mice Correlation of serum leptin levels with fat pad and body weight in MMTV-TGF-α mice. (a) Correlation between serum leptin levels and total fat pad 
(p < 0.0001; n = 49). (b) Correlation between serum leptin levels and total body weight (p < 0.0001; n = 49).
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Table 2
Mammary tumor incidence, latency, and weight and number for MMTV TGF-α mice
Overall mammary 
tumor incidence 
(percentage)
Palpable mammary 
tumor incidence 
(percentage)
Palpable mammary 
tumor latency, weeks
Mammary tumor 
weight, gramsa
Mammary tumor 
numbera
Obesity-Prone 26/30 (79)b,c 18/33 (55)d 74.1 ± 2.4e 2.407 ± 0.32f 3.9 ± 0.08
Obesity-Resistant 12/17 (71) 5/29 (29) 76.7 ± 2.1 1.298 ± 0.35g 3.5 ± 0.20
Low-Fat 11/20 (55) 2/20 (10) 81.9 ± 0.1 0.653 ± 0.29g 2.3 ± 0.18
aValues from tumor-bearing mice only: Obesity-Prone (n = 26), Obesity-Resistant (n = 12), and Low-Fat (n = 11). Analysis of variance for 
statistical comparison.
bChi-square p = 0.07 among the groups; Obesity-Prone versus Low-Fat, p = 0.06.
cLow-grade adenocarcinomas confirmed by histopathology except for six high-grade adenocarcinomas in six different Obesity-Prone mice.
dChi-square p = 0.0038 among the groups; Obesity-Prone versus Low-Fat, p = 0.0012; Obesity-Prone versus Obesity-Resistant, p = 0.09; 
Obesity-Resistant versus Low-Fat, p = 0.21.
eDifferences among groups significant by log-rank test, p = 0.0015. This was followed by proportional hazard model: Obesity-Prone versus Low-
Fat, p = 0.0041, and Obesity-Resistant versus Low-Fat, p = not significant.
Different superscripts (f and g) indicate significant difference.Breast Cancer Research    Vol 9 No 6    Dogan et al.
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Figure 2
Densitometric analysis of leptin signaling protein and mRNA expression levels in mammary tumor (MT) of Low-Fat and High-Fat mice Densitometric analysis of leptin signaling protein and mRNA expression levels in mammary tumor (MT) of Low-Fat and High-Fat mice. (a) Leptin sig-
naling protein expression in MT. (b) Leeptin mRNA expression levels in MT. Protein bands were obtained using Western blot analysis as described 
in Materials and methods. Results are the average of three and six MT samples of individual mice. *p < 0.05. HF, High-Fat; Jak2, Janus kinase 2; LF, 
Low-Fat; pSTAT3, phosphorylated signal transducer and activator of transcription 3; STAT3, signal transducer and activator of transcription 3.
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Figure 3
Densitometric analysis of leptin signaling protein and mRNA expression levels in mammary fat pad (MFP) from Low-Fat or High-Fat mice Densitometric analysis of leptin signaling protein and mRNA expression levels in mammary fat pad (MFP) from Low-Fat or High-Fat mice. (a) Leptin 
signaling proteins in MFP. Protein bands were obtained using Western blot analysis as described in Materials and methods. Data are from five Low-
Fat and four High-Fat mice. (b) Average densitometry of leptin signaling molecule mRNA expression levels in MFP. Average density values of the 
mRNA expression bands were from five Low-Fat and six High-Fat mice. *p < 0.05. HF, High-Fat; Jak2, Janus kinase 2; LF, Low-Fat; pSTAT3, phos-
phorylated signal transducer and activator of transcription 3; STAT3, signal transducer and activator of transcription 3.
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Low-Fat mice, the total PARP expression level was signifi-
cantly higher than that of High-Fat mice (p < 0.01) (Figure 5a).
On the other hand, there were no significant differences
between the two groups for cleaved PARP products (Figure
5b,c), although there was a trend for the 89-kDa product of
PARP (p = 0.08) to be higher in MFP obtained from Low-Fat
mice (Figure 5b).
The mitochondrial apoptosis pathway was also assessed by
determining the activity of caspase-3, which cleaves PARP.
Activity of caspase-3 was significantly higher, by 35%, in MTs
from Low-Fat versus High-Fat mice (p < 0.05) (Figure 6a,b).
Similarly, activity of caspase-3 in MFP obtained from Low-Fat
mice was 45% higher than that of High-Fat mice (p < 0.05)
(Figure 6b).
Levels of Bcl-xL protein expression were significantly (p  <
0.05) higher in MTs from Low-Fat mice compared with this
protein in MTs from High-Fat mice (Figure 7a). The expression
levels of Bax, Bcl-2, and pAkt proteins were similar in MT from
both groups (Figure 7a). In MFP, protein expressions of Bax
and Bcl-xL were significantly higher in Low-Fat mice (p < 0.05)
(Figure 7b). However, there were no differences in protein
expression levels of Bcl-2 and pAkt in MFP samples obtained
from the mice fed either low-fat or high-fat diets (Figure 7b).
Discussion
In the present study, we demonstrate that mice fed a high-fat
diet from 10 to 85 weeks of age and designated Obesity-
Prone had significantly higher body and fat pad weights and
higher serum leptin levels in comparison with mice fed the
same high-fat diet and designated as Obesity-Resistant or
Low-Fat. In addition, MT incidence and MT weights were
higher in Obesity-Prone mice compared with both Obesity-
Resistant and Low-Fat mice, and palpable MT latency was
shortened in Obesity-Prone mice compared with Low-Fat
mice. Interestingly, there were also differences in comparisons
between the Low-Fat and Obesity-Resistant mice despite
their similar body weights, such as a trend toward higher
palpable MT incidence and higher fat pad weights and serum
leptin levels in the Obesity-Resistant mice.
The findings of higher MT weights and presence of high-grade
adenocarcinomas in the Obesity-Prone mice indicate similari-
ties to the relationship of obesity with human breast cancer.
For example, obesity has been associated with bigger tumors,
more advanced disease, poorer prognosis, and/or increased
mortality in women with breast cancer [6]. The shortened MT
latency reported for Obesity-Prone mice is consistent with
human studies relating higher body weight/body mass index
with increased risk of breast cancer. For example, the pres-
Figure 4
Western blot analysis for poly(ADP-ribose)polymerase (PARP) protein expression in mammary tumor (MT) Western blot analysis for poly(ADP-ribose)polymerase (PARP) protein expression in mammary tumor (MT). Total (a) and cleaved PARP (b, c) protein 
expression levels were analyzed using Western blot analysis as described in Materials and methods. Data are average density values of three and six 
individual mice from Low-Fat (LF) and High-Fat (HF) groups, respectively. *p < 0.05.
A                                                    B              C
                                                                                                                   
LF               HF LF HF LF HF
P PARP-116 in MT
Low-Fat High-Fat
0
1
2
3
4
5

A
r
b
i
t
a
r
y
 
U
n
i
t
s
PARP-89 in MT
Low-Fat High-Fat
0.0
2.5
5.0
7.5
10.0
12.5
15.

A
r
b
i
t
a
r
y
 
U
n
i
t
s
0 ARP-24 in MT
Low-Fat High-Fat
0
2
4
6
8
10

A
r
b
i
t
a
r
y
 
U
n
i
t
sAvailable online http://breast-cancer-research.com/content/9/6/R91
Page 9 of 15
(page number not for citation purposes)
ence of obesity would promote the development of breast can-
cer sooner in susceptible women, who if they had stayed lean
might eventually die of causes other than breast cancer. Also,
if breast cancer did develop at a later age, its consequences
may have less impact on shortening life expectancy and/or
affecting quality of life. Furthermore, our results suggest that
body fat independent of body weight and obesity may be an
important factor in MT development as indicated by differ-
ences between Obesity-Resistant and Low-Fat mice. This was
seen by the many intermediate measurements for the Obesity-
Resistant mice and by the fact that gene expression data were
impacted more by consumption of the high-fat diet that
increased body fat levels.
A major focus of the present study was to determine the
i m p a c t  o f  d i e t  a n d / o r  b o d y  w e i g h t  o n  e x p r e s s i o n  o f  l e p t i n
signaling proteins in MFP and MT tissues. This was of interest
as a consequence of earlier studies indicating that the
absence of leptin and its receptor were associated with a lack
of MT development in transgenic MMTV-TGF-α mice [27,29].
The fact that the leptin receptor was identified in human breast
tumors and in human breast cancer cell lines and that the addi-
tion of leptin to breast cancer cell lines increased cell prolifer-
ation [17-19,41-43] further supported the involvement of
leptin in mammary tumorigenesis. Also, while this long-term
mouse experiment was under way, additional publications fur-
ther supported that leptin stimulates proliferation and affects
signal transduction in breast cancer cell lines [41-45].
Despite the increasing evidence that leptin impacts human
breast cancer cells in vitro, the role of leptin in the
development of human breast cancer per se is not clear. Some
studies have reported that breast cancer subjects have higher
serum leptin levels than controls, but others have not [46-50].
Since some of these studies focused on younger subjects or
combined pre- and postmenopausal women and subject num-
bers were small, it is not surprising that inconclusive results
have been obtained so far. Additionally, as in the present
Figure 5
Western blot analysis of poly(ADP-ribose)polymerase (PARP) protein expression in mammary fat pad (MFP) Western blot analysis of poly(ADP-ribose)polymerase (PARP) protein expression in mammary fat pad (MFP). Total (a) and cleaved PARP (b, c) pro-
tein expression levels were analyzed using Western blot analysis as described in Materials and methods. Data are average density values of five and 
four individual mice from Low-Fat (LF) and High-Fat (HF) groups, respectively. *p < 0.05.
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study, serum was obtained at only one time point, usually at
diagnosis. Several recent studies have suggested that serum
leptin levels in association with expression of leptin and/or lep-
tin receptor isoforms in breast tumors or with gene polymor-
phisms for leptin and its receptor may be more definitive in
identifying the impact of serum leptin on prognosis with
respect to disease recurrence and death [51,52]. Although as
indicated leptin and leptin receptor expression have been
identified in human breast tumors, proteins associated with
leptin signaling have not been characterized. In the present
study, we not only found that leptin receptors ObR and ObRb
are present in MTs obtained from MMTV-TGF-α mice, but we
detected the presence of Jak2 and pSTAT3 proteins, which
are located in the downstream pathway of leptin signaling.
These proteins were also shown to be expressed in MFP.
Additionally, the presence of leptin itself was detected in both
MFP and MT samples, indicating the potential for paracrine
and/or autocrine action of leptin. Furthermore, we found that
consumption of a high-fat diet was associated with lower pro-
tein expression levels of ObRb and Jak2 in MFP and with lower
ObRb, Jak2, and pSTAT3 protein expression levels in MT
samples.
Our findings of a reduction in ObRb and/or Jak2 and pSTAT3
protein expression levels are similar to previous reports for
effects of diet-induced obesity and consumption of high-fat
diets on these proteins in the hypothalamus. For example, in
male (Fischer 344 × Brown Norway) rats with diet-induced
obesity as a consequence of consumption of a high-fat diet,
ObRb protein and mRNA expressions were reported to be
reduced in the hypothalamus compared with chow controls
[53]. In addition, 30 days of calorie restriction after the 105
days of consuming the high-fat diet resulted in increased
ObRb and pSTAT3 protein expression in diet-induced obese
rats. In other studies, the reduction of leptin receptor expres-
sion levels in the hypothalamus of high-fat-fed Osborne-Men-
del rats [54] and C57BL6 mice [55] in comparison with low-
fat counterparts also parallels our findings in MFP and MT tis-
sues. In adipose tissue from male C57BL6 mice fed a high-fat
diet for 8 weeks, higher serum leptin levels were associated
Figure 6
Levels of caspase-3 activity in mammary tumor (MT) and mammary fat pad (MFP) Levels of caspase-3 activity in mammary tumor (MT) and mammary fat pad (MFP). (a) Caspase-3 activity in MT from three Low-Fat and six High-Fat 
mice. (b) Caspase-3 activity in MFP from five Low-Fat and four High-Fat mice. *p < 0.05.
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Figure 7
Densitometric analysis of apoptosis signaling pathway protein expression in mammary tumor (MT) and mammary fat pad (MFP) from MMTV-TGF-α  mice Densitometric analysis of apoptosis signaling pathway protein expression in mammary tumor (MT) and mammary fat pad (MFP) from MMTV-TGF-α 
mice. (a) MT samples obtained from three Low-Fat and six High-Fat mice. (b) MFP samples obtained from five Low-Fat and four High-Fat mice. *p < 
0.05. pAkt, phosphorylated Akt.
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with reduced expression levels of the short form of the leptin
receptor, although expression levels of the long form of the
leptin receptor were similar to those of low-fat control mice
[56]. This reduction in the leptin receptor and/or components
of the signaling pathway has been termed leptin resistance
and is associated with genetic and diet-induced obesities as
well as with aging [57-60].
In the present study, we also assessed effects of low-fat ver-
sus high-fat diets on expression levels of apoptosis-related
Table 3
Summary of diet effects on leptin and apoptosis signaling protein and mRNA expression levels
MT MFP
Leptin signaling molecules
Leptin NC NC NC
ObR NC NC
ObRb
Jak2 NM NM
pSTAT3 NC NC
Apoptosis signaling molecules
PARP (total)
PARP (89 kDa) NC
PARP (24 kDa) NC
Caspase-3 activity
Bax NC
Bcl-2 NC NC
Bcl-XL
pAkt NC NC
Jak2, Janus kinase 2; MFP, mammary fat pad; MT, mammary tumor; NC, no statistically significant change; NM, not measured; pAkt, 
phosphorylated Akt; PARP, poly(ADP-ribose)polymerase; pSTAT3, phosphorylated signal transducer and activator of transcription 3. Solid arrows 
show protein expression and dashed lines mRNA expression.Available online http://breast-cancer-research.com/content/9/6/R91
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proteins in MTs and MFP. All of the proteins, total PARP,
PARP-89, PARP-24, Bax, Bcl-2, Bcl-xL, and caspase-3
activity, were detected in both tissues. Furthermore, we found
that diet affected most of these proteins more than body
weight status, with the consumption of a high-fat diet being
associated with reduced apoptosis in both MTs and MFP.
Leptin has been reported to inhibit apoptosis in human colon
[37] and prostate [38] cancer cell lines and in leukemic cells
[39]. Since mice fed the high-fat diet had higher serum leptin
levels compared with those fed the low-fat diet, the lower
expression of these apoptotic proteins is consistent with in
vitro results. We also found that the consumption of a high-fat
diet resulted in significantly decreased cleaved PARP protein
expression levels in MT and MFP samples. In addition, the
activity of caspase-3, which cleaves total PARP, was lower in
MFP and MT tissues of the mice fed the high-fat diet. Both
caspase-3 and cleaved PARP products are involved in DNA
breakage and lead to apoptosis. Although in the present study
cell survival protein expression levels either did not change
(pAkt and Bcl-2) or were decreased (Bcl-XL) in high-fat diet
mice that also had higher serum leptin levels, in an in vitro
study with HTB-26 and ZR75-1 breast cancer cell lines, it was
shown that leptin increased the expression levels of pERK
(phosphorylated extracellular signal-regulated kinase) and
pAkt [41]. This difference may well be a consequence of the
different study designs (in vitro versus in vivo). In particular, in
the present study, tissues were removed after long-term diet
maintenance and exposed to many other hormones and
cytokines in addition to leptin in the body, whereas in the other
study, cells were maintained with leptin for only 48 hours after
serum deprivation for 20 hours in vitro.
A summary of the results of protein and mRNA expression lev-
els is presented in Table 3. The effects of high-fat diet relative
to low-fat diet were similar on the expression levels of leptin,
ObR, ObRb, Jak2, total PARP, caspase-3, Bcl-2, Bcl-Xl, and
pAkt protein both in MT and MFP tissues. Overall changes that
did occur were primarily in the direction of reduced apoptosis
in the MFP and MT tissues obtained from mice fed the high-fat
diet. The present study is the first to show that consumption of
a high-fat diet (for 75 weeks) has effects on pro-apoptotic and
survival protein expression levels in MTs and MFP. However,
several previous publications have studied the effects of calo-
rie restriction on similar protein expression levels. For example,
levels of pro-apoptotic Bax, caspase-3 activity, and cleaved
PARP products were all higher in MTs from energy-restricted
rats (40% reduction) compared with MTs from ad libitum-fed
rats, whereas Bcl-2 and pAkt were reduced [61]. In another
study, using MTs obtained from energy-restricted MMTV-TGF-
α mice, caspase-3 activity and DNA breakage were elevated
in mice subjected to 50% restriction but not to 25%, but pAkt
was not affected [62]. In the present study, consumption of a
high-fat diet resulted in little change on cell survival proteins
(Bcl-2, Bcl-xL, and pAkt) in MT as well as MFP tissues, with the
primary effect of consumption of the high-fat diet resulting in
reduced apoptosis. Thus, calorie restriction appears to pro-
mote apoptosis in MTs whereas consumption of the
moderately high-fat diet, even without effects on caloric intake,
did not.
Although it is documented that consumption of high-fat diets
shortens MT latency, the molecular mechanism mediating this
effect is unknown. In the present study, we report that mice
that were fed a high-fat diet and that became obese had higher
MT incidence and serum leptin levels, which were correlated
with total fat pad and body weights. We also demonstrated
that expression levels of leptin and apoptotic-associated pro-
teins were modulated by long-term high-fat diet consumption.
Leptin resistance appears to be associated with high-fat diet
consumption in both MTs and MFP, and an anti-apoptotic pro-
tein profile characterizes the MTs from mice fed the high-fat
diet. At this point, it is not clear what would happen at time
points prior to the development of leptin resistance and how
this would relate to MT development.
Conclusion
These results indicate that dietary-induced obesity enhances
MT development in MMTV-TGF-α mice compared with mice
that were fed the same high-fat diet and that did not become
obese as well as with mice that were fed a low-fat diet.
However, the expressions of a number of proteins associated
with leptin and leptin signaling in both the MTs that formed and
in MFP tissues were primarily affected by diet. This may be a
result of the long-term consumption of the high-fat diet leading
to leptin resistance. Future studies will be directed toward
shorter-term diet intervention and specific effects on mammary
tissues, particularly epithelial cells, to try to identify mechanis-
tic explanations for how body fat could impact MT develop-
ment. More studies need to be done to clarify how other
signaling proteins and pathways are affected by low-fat versus
high-fat diets as well as by caloric restriction and body weight/
body fat changes, so that pharmacological drugs can be
developed to target those molecules.
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